Nanobiotix S.A Asset Resilience Ratio
Nanobiotix S.A asset resilience ratio. Nanobiotix S.A (NANO) has an Asset Resilience Ratio of 53.40% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Nanobiotix S.A to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Nanobiotix S.A (2016–2024)
Asset resilience ratio of Nanobiotix S.A from 2016 to 2024. This chart shows how Nanobiotix S.A's Asset Resilience Ratio has changed over time. Read Nanobiotix S.A (NANO) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Nanobiotix S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Nanobiotix S.A.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €24.12 Million | 53.4% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €24.12 Million | 53.40% |
Asset Resilience Insights
- Very High Liquidity: Nanobiotix S.A maintains exceptional liquid asset reserves at 53.40% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Nanobiotix S.A Industry Peers by Asset Resilience Ratio
Compare Nanobiotix S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Nanobiotix S.A Asset Resilience Ratio by Year (2016–2024)
Nanobiotix S.A asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Nanobiotix S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 65.90% | €44.43 Million ≈ $51.94 Million |
€67.42 Million ≈ $78.82 Million |
-- |
| 2023-12-31 | 0.00% | €0.00 ≈ $0.00 |
€93.90 Million ≈ $109.78 Million |
-- |
| 2022-12-31 | 4.70% | €2.81 Million ≈ $3.29 Million |
€59.77 Million ≈ $69.88 Million |
-- |
| 2020-12-31 | 0.00% | €0.00 ≈ $0.00 |
€133.93 Million ≈ $156.57 Million |
-- |
| 2019-12-31 | 17.83% | €10.00 Million ≈ $11.69 Million |
€56.07 Million ≈ $65.56 Million |
-7.07pp |
| 2018-12-31 | 24.90% | €11.50 Million ≈ $13.45 Million |
€46.20 Million ≈ $54.01 Million |
+5.91pp |
| 2017-12-31 | 18.99% | €10.91 Million ≈ $12.76 Million |
€57.47 Million ≈ $67.18 Million |
-50.27pp |
| 2016-12-31 | 69.26% | €21.06 Million ≈ $24.62 Million |
€30.40 Million ≈ $35.54 Million |
-- |
About Nanobiotix S.A
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more